Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company’s Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao’s independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma’s continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a...